首页> 外文期刊>China Economic Journal >Biases in patent examination and firms' responses: Evidence from the pharmaceutical industry
【24h】

Biases in patent examination and firms' responses: Evidence from the pharmaceutical industry

机译:专利审查中的偏见和企业的回应:来自制药行业的证据

获取原文
获取原文并翻译 | 示例
           

摘要

Empirical analysis of matched patent application data in the world's major patent offices has shown considerable variation in patent granting probability and examination duration across different countries. This phenomenon is attributed to institutional misclassifications or patent examiners' mistakes by some authors. Others argued that cross-country heterogeneity could also be caused by deliberate manipulation of patent examination procedures with the goal to foster native inventors through suppressing foreign patent applicants. To explore whether manipulation exists, this study presents a case study of pharmaceutical patents granted by the US patent office and approved by the US FDA. Especially it focuses on the filing behavior of pharmaceutical companies in Korea, Japan and China. The regression results show that the granting ratio of the previous applications of a foreign company is correlated with the company's probability of lodging a new patent application, which provides a supplementary evidence of the existence of the manipulated patent examination procedures.
机译:对世界主要专利局中匹配的专利申请数据进行的经验分析表明,不同国家的专利授予概率和审查期限存在很大差异。这种现象归因于某些作者的机构分类错误或专利审查员的错误。其他人则认为,跨国异质性也可能是由于故意操纵专利审查程序而引起的,目的是通过抑制外国专利申请人来培养本国发明人。为了探讨是否存在操纵,本研究提供了由美国专利局授予并由美国FDA批准的药品专利的案例研究。尤其着重于韩国,日本和中国的制药公司的备案行为。回归结果表明,外国公司以前的申请的授予比率与该公司提出新专利申请的可能性相关,这为存在操纵专利审查程序提供了补充证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号